LU TIANBAO,ALEXANDER RICHARD,CONNORS RICHARD W.,CUMMINGS MAXWELL D.,GALEMMO ROBERT A.,HUFNAGEL HEATHER RAE,JOHNSON DANA L.,KHALIL EHAB,LEONARD KRISTI A.,MARKOTAN THOMAS P.,MARONEY ANNA C.,SECHLER JAN,HUFNAGE
申请号：
PL06847749
公开号：
PL1966214T3
申请日:
2006.12.18
申请国别(地区):
PL
年份:
2017
代理人:
摘要：
The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
